Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 8/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | EP300 | Q09472 | 4/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403709 | 0.91 | TNF (0.49) | TNFP2RX7FFAR4RORC | |
| SCHEMBL2470686 | 0.83 | MAPT (0.48) | FFAR4RORC | |
| SCHEMBL5487411 | 0.83 | P2RX7 (0.54) | P2RX7FFAR4 | |
| SCHEMBL4459699 | 0.82 | TNF (0.56) | TNFEP300CNR1MCL1 | |
| SCHEMBL4327022 | 0.81 | HDAC1 (0.53) | P2RX7RORCHDAC3HDAC1HDAC2 | |
| SCHEMBL29167257 | 0.80 | TNF (0.51) | TNFCNR1 | |
| SCHEMBL4466329 | 0.79 | TNF (0.60) | TNFCNR1MCL1 | |
| SCHEMBL413159 | 0.78 | FFAR4 (0.55) | P2RX7FFAR4RORCMCL1 | |
| SCHEMBL1664268 | 0.78 | TNF (0.56) | TNFEP300CNR1MCL1 | |
| SCHEMBL17242289 | 0.77 | P2RX7 (0.56) | P2RX7FFAR4RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20080319044-A1 | Compounds and Methods of Use Thereof | NUADA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2007134169-A9 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA LLC (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2006050236-A2 | COMPOUNDS AND METHODS OF USE THEREOF | NUADA, LLC (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006050236-A2 | COMPOUNDS AND METHODS OF USE THEREOF | NUADA, LLC (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | TNF, NFKBIA, IL6 | TNF 1/4885P2RX7 1824/4885EP300 3970/4885 |
| US-20080319044-A1 | Compounds and Methods of Use Thereof | TNF, LITAF, LTA | TNF 1/4885P2RX7 1268/4885EP300 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.